 |
|
|
25 November 2009 Report on the global market for prostate cancer therapeuticsGrowth in prostate cancer therapies can be asociated to the increase in number of prostate cancer incidences in men aged more than 60 years. Given the longevity of an average individual, and the rapidly aging world population, the risk of prostate cancer stands tall. Invasive cancer carries a high risk of spreading to the bone if left untreated, thereby making timely intervention of crucial importance. The market for world prostate cancer therapeutics continues to gain traction as companies explore advancements and improvements in drug delivery techniques translating to greater market opportunity. Several options exist for treating prostate cancer in its early development stage. Radiation therapy or surgery offer effective cure when the disease is diagnosed in initial stages. External Beam Radiation Therapy entails release of radioactive beams, either exclusively to the prostate gland (radiation only for prostate) or may cover the adjacent pelvic lymph glands besides the prostate gland (full pelvic radiation). In Brachytherapy or crevice insertions, the surgeon keeps tiny seeds or pallets of radioactive substance straight inside the prostate gland. These and other market data and trends are presented in "Prostate Cancer Therapeutics: A Global Market Perspective," by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses. SOURCE Reportlinker NOTE: Issues on this site regarding prostate cancer and treatment options, are provided for information only, and are not meant to substitute for the advice of your own physician or other medical professional. Prostate-Report.org does not endorse any specific product, service or treatment. |
|